The strength of female sex as a prognostic factor in small-cell lung cancer: A pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 232-237

  Wheatley Price, P ^a   Ma, C ^a   Ashcroft, L F ^b   Nankivell, M ^c   Stephens, R J ^c   White, S C ^b   Lorigan, P ^b   Thatcher, N ^b   Blackhall, F H ^b   Shepherd, F A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Chemotherapy; Sex; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROPATHY; OVERALL SURVIVAL; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOCYTOPENIA; CLINICAL TRIAL; LUNG SMALL CELL CANCER; LUNG TUMOR; MEDICAL SOCIETY; META ANALYSIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; FEMALE; GREAT BRITAIN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SEX FACTORS; SMALL CELL LUNG CARCINOMA; SOCIETIES, MEDICAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77951909080     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp300     Document Type: Article

References (30)

1. Hinson JA Jr, Perry MC. Small cell lung cancer. CA Cancer J Clin 1993; 43: 216-225.
2. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539-4544.
3. Polednak AP. Lung cancer incidence trends in black and white young adults by gender (United States). Cancer Causes Control 2004; 15: 665-670.
4. Sahmoun AE, Case LD, Santoro TJ, Schwartz GG. Anatomical distribution of small cell lung cancer: effects of lobe and gender on brain metastasis and survival. Anticancer Res 2005; 25: 1101-1108.
5. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8: 1563-1574.
6. Crown JP, Chahinian AP, Jaffrey IS et al. Predictors of 5-year survival and curability in small cell lung cancer. Cancer 1990; 66: 382-386.
7. Johnson BE, Steinberg SM, Phelps R et al. Female patients with small cell lung cancer live longer than male patients. Am J Med 1988; 85: 194-196.
8. Osterlind K, Hansen HH, Hansen M et al. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol 1986; 4: 1307-1313.
9. Paesmans M, Sculier JP, Lecomte J et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000; 89: 523-533.
10. Singh S, Parulekar W, Murray N et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 2005; 23: 850-856.
11. Spiegelman D, Maurer LH, Ware JH et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989; 7: 344-354.
12. Videtic GM, Truong PT, Ash RB et al. Does sex influence the impact that smoking, treatment interruption and impaired pulmonary function have on outcomes in limited stage small cell lung cancer treatment? Can Respir J 2005; 12: 245-250.
13. Wolf M, Holle R, Hans K et al. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer 1991; 63: 986-992.
14. Lorigan P, Woll PJ, O'Brien ME et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in betterprognosis small-cell lung cancer. J Natl Cancer Inst 2005; 97: 666-674.
15. White SC, Lorigan P, Middleton MR et al. Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer 2001; 92: 601-608.
16. Baka S, Califano R, Ferraldeschi R et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 2008; 99: 442-447.
17. Thatcher N, Girling DJ, Hopwood P et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial, Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000; 18: 395-404.
18. Thatcher N, Qian W, Clark PI et al. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol 2005; 23: 8371-8379.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
20. Mascaux C, Paesmans M, Berghmans T et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000; 30: 23-36.
21. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatincontaining regimen versus a regimen without this alkylating agent. Br J Cancer 2000; 83: 8-15.
22. Albain KS, Unger J, Gotay CC et al. Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol 2007; 25: (Abstr 7549).
23. Vina J, Borras C, Gambini J et al. Why females live longer than males: control of longevity by sex hormones. Sci Aging Knowledge Environ 2005; 2005: pe17.
24. Woloshin S, Schwartz LM, Welch HG. The risk of death by age, sex, and smoking status in the United States: putting health risks in context. J Natl Cancer Inst 2008; 100: 845-853.
25. Wheatley-Price P, Le Maitre A, Ding K et al. The influence of sex on efficacy, toxicity and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) non-small cell lung cancer (NSCLC) chemotherapy trials. J Clin Oncol 2008; 26: (Abstr 8054).
26. Belani CP, Von Pawel J, Pluzanska A et al. Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): analyses by gender. Lung Cancer 2006; 49S: 235-236.
27. Stadler M, Bardiau F, Seidel L et al. Difference in risk factors for postoperative nausea and vomiting. Anesthesiology 2003; 98: 46-52.
28. Wakelee HA, Wang W, Schiller JH et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 2006; 1: 441-446.
29. Hesketh PJ, Grunberg SM, Herrstedt J et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006; 14: 354-360.
30. Sloan JA, Loprinzi CL, Novotny PJ et al. Sex differences in fluorouracil-induced stomatitis. J Clin Oncol 2000; 18: 412-420.